EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
Explore this paper's citation graph
Summary
Liver biopsy gives a snapshot and not an insight into the dynamic changes during the process of fibrogenesis, so immunohistochemical evaluation of cellular markers such as smooth muscle actin expression for hepatic stellate cell activation, cytokeratin 7 for labeling ductular proliferation or CD34 for visualization of sinusoidal endothelial capillarization can provide additional ‘‘functional’’ information.
- Type
- article
- Published
- 2015-07-01
- Cited by
- 1,825
- References
- 338
- Access
- Open access
- OpenAlex
- https://openalex.org/W216121951
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:140130064
Keywords
Liver biopsy, Cirrhosis, Fibrosis, Pathology, Medicine
References
- Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort
- An ROC‐type measure of diagnostic accuracy when the gold standard is continuous‐scale
- Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
- Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis
- Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B.
- Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients.
- Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis.
- Acoustic Radiation Force Impulse (ARFI)--a new modality for the evaluation of liver fibrosis.
- Chronic hepatitis B : an update
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
- Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B
- The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases
- Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis
- Disproportionally high results of transient elastography in patients with autoimmune hepatitis
- Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
- Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease
- Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population
- Development of a non‐invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B
- Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.
Cited by
- Nonalcoholic fatty liver disease
- Clinical usefulness and performance of acoustic radiation force impulse in patients with chronic hepatitis B
- Ultrasound Elastography: Review of Techniques and Clinical Applications
- Proteomic profiling of HBV infected liver biopsies with different fibrotic stages
- [The news in hepatitis C therapy].
- Hepatitis B: Who and when to treat?
- Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels
- Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update
- Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection
- Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East
- Hepatocellular carcinoma risk in hepatitis C stage‐3 fibrosis after sustained virological response with direct‐acting antivirals
- Liver Function—How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives
- Inflammation‐adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease
- Valid confidence intervals for post-model-selection predictors
- Is it really worth adapting liver stiffness cut‐offs according to AST levels?
- Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis C
- Contemporary use of elastography in liver fibrosis and portal hypertension
- Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.
- Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
- Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?
Related papers
- Research progress on the relationship between transforming growth factor-β1 and hepatic fibrosis
- Effectiveness of saponins from Panax notoginseng against hepatic fibrosis
- A Selective PPARγ Modulator Reduces Hepatic Fibrosis
- Non-Invasively Distinguishing Progress of Liver Fibrosis by Visualizing Hepatic Platelet Derived Growth Factor Receptor-Beta Expression with an MRI Modality in Mice
- Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets.
- [Expression of TIMP-1 and TGF-beta1 mRNA in hepatic fibrosis rats and the therapeutic effects of Bushen Rougan Recipe].
- Effects of suramin on proliferation and apoptosis of hepatic stellate cells of hepatic fibrosis rats
- M1581 Anti-Copper Therapy Protects Against Hepatic Fibrosis By Down-Regulating Collagen Iα1 mRNA Expression in Hepatic Stellate Cells
- Hepatic cellular microenvironment:a novel drug target for anti-hepatic fibrosis
- Traditional Chinese medicine targets on hepatic stellate cells for the treatment of hepatic fibrosis: A mechanistic review